跳转至内容
Merck
CN

SML1099

罗氟司特

≥98% (HPLC), powder, phosphodiesterase 4 PDE4 inhibitor

别名:

3-(环丙基甲氧基)-N-(3,5-二氯吡啶-4-基)-4-(二氟甲氧基)苯甲酰胺, 3-环丙基甲氧基-4-二氟甲氧基-N-[3,5-二氯-4-吡啶基]-苯甲酰胺

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C17H14Cl2F2N2O3
化学文摘社编号:
分子量:
403.21
UNSPSC Code:
41106305
PubChem Substance ID:
NACRES:
NA.77
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

罗氟司特, ≥98% (HPLC)

SMILES string

ClC1=CN=CC(Cl)=C1NC(C2=CC=C(OC(F)F)C(OCC3CC3)=C2)=O

InChI

1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)

InChI key

MNDBXUUTURYVHR-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 20 mg/mL, clear

storage temp.

−20°C

Quality Level

Gene Information

正在寻找类似产品? 访问 产品对比指南

Application

罗氟司特已被用于评估其对小鼠熏烟法模型中急性肺部炎症和慢性肺部改变的影响。此外,它还可用于研究其在长期增效 (LTP)缓解原胚细胞诱发的缺陷方面的治疗潜力。

Biochem/physiol Actions

罗氟司特是一种高效、口服有效的选择性磷酸二酯酶4 (PDE4) 抑制剂。
罗氟司特是一种高效、口服有效的选择性磷酸二酯酶4 (PDE4) 抑制剂,IC50 为 0.8 nM。罗氟司特具有抗炎作用,用于临床治疗COPD。

Features and Benefits

这种化合物是环核苷酸研究的特色产品。点击此处发现更多特色环核苷酸产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Christian de Mey et al.
BMC clinical pharmacology, 11, 7-7 (2011-06-03)
Roflumilast is an oral, selective phosphodiesterase 4 inhibitor with anti-inflammatory effects in chronic obstructive pulmonary disease (COPD). The addition of roflumilast to long-acting bronchodilators improves lung function in patients with moderate-to-severe COPD. The present study investigated drug-drug interaction effects between
Fernando J Martinez et al.
Lancet (London, England), 385(9971), 857-866 (2015-02-17)
Roflumilast reduces exacerbations in patients with severe chronic obstructive pulmonary disease. Its effect in patients using fixed combinations of inhaled corticosteroids and longacting β2 agonists is unknown. We postulated that roflumilast would reduce exacerbations in patients with severe chronic obstructive
Phosphodiesterase-4 inhibition restored hippocampal long term potentiation after primary blast.
Vogel E W, et al.
Experimental Neurology, 293, 91-100 (2017)
Innocence Harvey et al.
Obesity (Silver Spring, Md.), 31(7), 1859-1870 (2023-05-31)
Prescription glucocorticoid (GC) use is widespread across developed countries for the treatment of several inflammatory conditions. Elevated GCs are known to promote lipolysis and metabolic disorders. An extract of Artemisia scoparia (SCO) has been shown to reduce lipolysis and promote
Xiaohua Du et al.
Phytotherapy research : PTR, 33(3), 602-609 (2019-01-15)
The principal active component of isoforskolin (ISOF) is from the plant Coleus forskohlii, native to China, which has attracted much attention for its biological effects. We hypothesize that ISOF and forskolin (FSK) pretreatment attenuates inflammation induced by lipopolysaccharide (LPS) related

商品

Cyclic nucleotides like cAMP modulate cell function via PKA activation and ion channels.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持